Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.485 AUD | -6.73% | -5.83% | -14.91% |
May. 28 | Opthea Limited Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD | CI |
May. 28 | Opthea Completes Enrollments in COAST, ShORe Trials | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.91% | 212M | |
+49.41% | 56.95B | |
+39.98% | 40.26B | |
-6.72% | 39.32B | |
-5.96% | 28.37B | |
+12.99% | 26.45B | |
-19.82% | 19.41B | |
+32.35% | 12.54B | |
+25.18% | 12.21B | |
-0.08% | 12.15B |
- Stock Market
- Equities
- OPT Stock
- News Opthea Limited
- Opthea Secures $85 Million for Advancing Clinical Trials, Pre-Commercialization Activities